Werewolf Therapeutics Sells Asset to Jazz in Major Strategic Overhaul

WATERTOWN, Mass. – May 07, 2026 – Werewolf Therapeutics, an innovative biopharmaceutical company known for its conditionally activated cancer therapies, today announced a series of significant strategic moves aimed at shoring up its financial position as it evaluates its future path. In conjunction with its first-quarter 2026 financial results, the company revealed it has sold a key pipeline asset to Jazz Pharmaceuticals, fully repaid a major loan, and is actively exploring a range of strategic alternatives to maximize shareholder value.

The moves signal a critical juncture for the Watertown-based firm, which has been developing a novel class of immune-stimulating drugs. The company has retained Piper Sandler & Co. as its exclusive financial advisor to navigate this process, which could include a merger, a sale of the company, or further licensing deals for its remaining programs.

“Werewolf, assisted by its exclusive financial advisor, Piper Sandler & Co. (“Piper Sandler”), continues to explore a range of alternatives available to the Company to maximize shareholder value,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, in a statement. The company has not set a timeline for this review and stated it will not provide further updates unless a specific action is approved.

A Financial Overhaul to Extend the Runway

The most significant development is an asset purchase agreement with Jazz Pharmaceuticals, which gives Jazz exclusive global rights to JZP898, an interferon-alpha (IFNα) program. The deal, which closed on May 6, provided Werewolf with an immediate upfront payment of $21 million.

This cash infusion was immediately deployed. Werewolf announced it has fully repaid all outstanding obligations, totaling approximately $31.4 million, under a loan and security agreement with K2 HealthVentures. This deleveraging maneuver cleans up the company's balance sheet but also underscores the financial pressures it faces.

As of March 31, 2026, Werewolf reported cash and cash equivalents of $46.5 million, down from $57.1 million at the end of 2025. After accounting for the influx of cash from the Jazz deal and the outflow for the K2 loan repayment, the company's pro forma cash position is significantly altered. Further impacting its cash are a $2.7 million fee to terminate its headquarters lease early and $4.3 million in charges related to a major restructuring plan announced earlier this year, which included a 64% reduction in its workforce.

These actions come as the company reported a net loss of $13.5 million for the first quarter of 2026. While this is an improvement from the $18.1 million loss in the same period last year, driven by a decrease in research and development expenses, the ongoing cash burn remains a central challenge. In its filings, management has disclosed that there is "substantial doubt" about the company's ability to continue as a "going concern" without securing additional financing or executing a strategic transaction, a stark warning to investors about its precarious financial state.

Divesting a Promising Asset

The sale of the JZP898 program to Jazz Pharmaceuticals is more than a simple transaction; it represents a full divestiture of an asset that was once a key part of a promising collaboration. Jazz had initially licensed the program, then known as WTX-613, from Werewolf in April 2022 for a $15 million upfront payment, with Werewolf eligible for over a billion dollars in potential milestones.

By converting this partnership into an outright sale, Werewolf forgoes those potential long-term rewards for immediate, non-dilutive capital. The move highlights a strategic decision to prioritize near-term survival over future upside from this specific program. Jazz, for its part, is already advancing JZP898 in a Phase 1 clinical trial for patients with advanced or metastatic solid tumors, both as a standalone therapy and in combination with pembrolizumab, signaling its confidence in the asset's potential.

The Value of the Remaining Pack

With JZP898 sold, attention now turns to the value and potential of Werewolf's remaining pipeline, which is built on its proprietary PREDATOR® platform. This technology designs INDUKINE™ and INDUCER™ molecules that are engineered to remain inactive until they reach the tumor microenvironment, a strategy intended to maximize efficacy while minimizing the severe side effects associated with conventional immunotherapies.

Werewolf's most advanced clinical candidate is WTX-124, a conditionally activated Interleukin-2 (IL-2) molecule. The program has received Fast Track Designation from the FDA for advanced melanoma and has shown promising early data, including a 30% overall response rate in a subset of melanoma patients who had previously responded to immunotherapy. The FDA has provided initial guidance for a potential registration path, making WTX-124 a highly valuable asset for which the company is actively seeking a strategic partner.

Slightly behind it is WTX-330, a conditionally activated Interleukin-12 (IL-12) molecule. This program has demonstrated a favorable tolerability profile, a significant achievement given the historical toxicity challenges of IL-12 therapies, and has shown early signs of antitumor activity, including a confirmed partial response in a patient with metastatic gallbladder cancer. Like WTX-124, the future development of WTX-330 is contingent on securing a partnership or additional funding.

Further back in the pipeline are two preclinical INDUCER molecules, which are designed as T-cell engagers. WTX-1011 targets STEAP1, an antigen highly expressed in prostate cancer, while WTX-2022 targets CDH6, found in ovarian and kidney cancers. Both targets are the subject of intense industry interest, with major players like Amgen and Daiichi Sankyo developing competing therapies. However, Werewolf has stated that filing Investigational New Drug (IND) applications for these programs, planned for mid-2027, is dependent on raising more capital. Their value remains largely potential, hinging entirely on the company's ability to fund their progression into the clinic.

As Werewolf Therapeutics navigates this pivotal period, the company's future rests on the outcome of its strategic review. The sale to Jazz and the repayment of debt have provided some breathing room, but the clock is ticking. The fate of its promising, conditionally activated therapies and the company itself now depends on its ability to attract a partner, a buyer, or another source of significant investment to carry its innovative science forward.